First Single-Centre Experience with the Novel HIF-α Inhibitor Belzutifan in Switzerland

First Single-Centre Experience with the Novel HIF-α Inhibitor Belzutifan in Switzerland

Belzutifan is a new HIF-α inhibitor mainly used in two different indications: von Hippel–Lindau syndrome-associated renal cell carcinoma, haemangioblastomas and pancreatic neuroendocrine tumours, as well as sporadic advanced pre-treated renal cell carcinoma. Although efficacy has been demonstrated i...

Full description

Saved in:
Bibliographic Details
Main Authors: Tobias Peres, Stefanie Aeppli, Stefanie Fischer, Thomas Hundsberger, Christian Rothermundt
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Current Oncology
Subjects:
belzutifan
HIF-α inhibitor
von Hippel–Lindau syndrome
renal cell carcinoma
haemangioblastomas
case series
Online Access:https://www.mdpi.com/1718-7729/32/2/64
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items